Sihuan Pharmaceutical Holdings Group Ltd. (FRA:TEL1)
Germany · Delayed Price · Currency is EUR | Market Cap | 953.18M +30.8% |
| Revenue (ttm) | 318.79M +37.7% |
| Net Income | 21.88M |
| EPS | 0.00 |
| Shares Out | n/a |
| PE Ratio | 43.56 |
| Forward PE | n/a |
| Dividend | 0.00 (1.15%) |
| Ex-Dividend Date | Sep 26, 2025 |
| Volume | n/a |
| Open | 0.1040 |
| Previous Close | 0.1030 |
| Day's Range | 0.1040 - 0.1040 |
| 52-Week Range | 0.0965 - 0.2080 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 28, 2026 |
About FRA:TEL1
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical and medical aesthetic products in the People’s Republic of China, the United States, and internationally. It operates in three segments: Medical Aesthetic Products, Innovative Medicine and Other Medicine, and Generic Medicine. The company offers filling, shaping, supporting, supplementing, optoelectronic devices, body sculpturing, skin care, and other services, as well as non- or minimally invas... [Read more]
News
Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical, Its Innovative Drug Anaprozole Sodium Enteric-coated Tablets Obtains Drug Registration Approval From NMPA
HONG KONG , June 27, 2023 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd together with its subsidiaries, is pleased to announce that Xuanzhu Biopharmaceutical Co., Ltd. ("Xuanzhu Biopharm"),...